Skip to main content
. 2020 Oct 15;12(10):976. doi: 10.3390/pharmaceutics12100976

Figure 7.

Figure 7

Correlation between MSLI FPF%≤5 μm and APS FPF%≤5 μm using the particle density calculated by the conversion factor. Values of APS FPF%≤5 μm using the particle density described in Table 2 (mean ± S.E., n = 3) were plotted against values of MSLI FPF%≤5 μm (mean ± S.E., n = 3). MSLI, multi-stage liquid impinger; FPF, fine particle fraction; APS, aerodynamic particle sizer; hGhrelin, hGhrelin formulation containing 0.1 mg/vial of hGhrelin and 0.5 mg/vial of Phe; VB3, VB3 formulation containing 0.1 mg/vial of VB3 and 0.5 mg/vial of Phe; VB12, VB12 formulation containing 0.1 mg/vial of VB12 and 0.6 mg/vial of Phe; Am80, Am80 formulation containing 0.1 mg/vial of Am80 and 0.1 mg/vial of Phe; Phe, placebo formulation containing 0.2 mg/vial of Phe.